Abstract:Belatacept, a high-affinity variant of CTLA4-Ig, is a recently approved immunosuppressive agent for the prevention of acute rejection. It functions as a potent antagonist of the CD28-B7 interactions, thereby inhibiting T cell co-stimulation and activation. Experimental data involving the transient use of CTLA4-Ig to induce allograft tolerance have shaped the current paradigm that CTLA-4Ig is ineffective at inhibiting memory T cell responses, and by extension T-dependent alloantibody responses. This resistance is explained by the acquisition of additional activation-induced costimulatory molecules by memory T cells. We noted that the efficacy of CTLA4-Ig as a continuously administered drug for controlling rejection in sensitized recipients has not been investigated. Here we report on the efficacy of CTLA4-Ig in preventing acute rejection in sensitized C57BL/6 recipients that had received BALB/c spleen cell transfusion 3-6 months previously. We set up four experimental groups. Group 1 (N=5): sensitized mice with HTX and CTLA4-Ig treated (Day -2, Day 0, Day2, then weekly (1 mg/dose) Group 2 (N=3): sensitized mice with HTX and no CTLA4-Ig, Group 3: (N=10) naive mice with HTX and CTLA4-Ig treated, Group 4 (N=10): naive mice with HTX and no CTLA4-Ig. In the untreated Groups 2 & 4, allografts were rejected within 7 days post-transplantation, whereas in Group 3 of naive mice receiving CTLA4-Ig, all the grafts survived long-term (>90 days). In Group 1 of sensitized recipients receiving CTLA4-Ig, the allografts survived for 42, 42, 49, >90, >90 days. The pre-transplant donor-specific antibody (DSA) titers in the recipients that went on to reject their graft was significantly higher compared to those that accepted their grafts. Furthermore, DSA titers increased post-transplantation in the recipients that went on to reject their allografts, whereas DSA titers decreased in those that accepted their grafts. In conclusion, these observations illustrate the efficacy of CTLA-4Ig treatment at controlling rejection in sensitized recipients, and underscore the barrier pre-transplantation DSA poses to long-term graft acceptance. This experimental model also provides a unique opportunity for testing if DSA promotes antibody-mediated rejection or alloreactive memory T cell priming and T cell-mediated rejection in CTLA4-Ig treated recipients, and for identifying therapies that promote long-term graft survival in sensitized recipients.

Low Dose Interleukin-2 Induces Exosomes with Tolerance Markers (PDL1, CD73) and Significantly Delays Development of Chronic Rejection Following Murine Heterotopic Cardiac Transplantation

Efficacy of Ctla4-Ig in Preventing Acute Rejection of Fully Allogeneic Heart Allografts in Sensitized Recipients

Tolerance Induced by IL-6 Deficient Donor Heart is Significantly Involved in Myeloid-Derived Suppressor Cells (Mdscs).

Cardiac Allograft Tolerance Induced by Isogeneic CD4+CD25+ Regulatory T Cells.

Role for Circulating Exosomes with Cardiac Self-Antigens (myosin and Vimentin) in the Pathogenesis of Chronic Rejection in a Murine Heterotopic Model of Cardiac Transplantation

Exosomes from Rejected Syngeneic Cardiac Grafts Express Myosin and Vimentin and Immunoregulatory miRNA and Induce Graft Rejection

leukin-15 (IL-15) production during acute rejection following heart transplantation in mice. Inbred male Balb/c (H-2d) and C57BL/6 (H-2b) mice were used to establish a heterotopic intra-abdominal cardiac transplantation model. The mice were divided in four groups: syngeneic control, allogeneic acute

Combination of C-X-C motif chemokine 9 and C-X-C motif chemokine 10 antibodies with FTY720 prolongs the survival of cardiac retransplantation allografts in a mouse model

Circulating Exosomes with Lung Self-Antigens, Kα1Tubulin and Collagen V, and Immune Responses to Lung Self-Antigens Precedes Histological Evidence of Chronic Rejection Following Orthotopic Murine Lung Transplantation

Exosomes derived from microRNA-540-3p overexpressing mesenchymal stem cells promote immune tolerance via the CD74/nuclear factor-kappaB pathway in cardiac allograft

Alteration Of Innate Immunity By Donor Il-6 Deficiency In A Presensitized Heart Transplant Model

Mechanism Exploration on the Immunoregulation of Allogeneic Heart Transplantation Rejection in Rats With Exosome miRNA and Proteins From Overexpressed IDO1 BMSCs

Regulation of cardiac allograft immune responses by microRNA-155

Selective Immunosuppression with Anti-Interleukin-2 Receptor-Targeted Therapy - Helper and Suppressor-Cell Activity in Rat Recipients of Cardiac Allografts

Tolerance Induction by Exosomes from Immature Dendritic Cells and Rapamycin in a Mouse Cardiac Allograft Model.

The Relations Between Interleukin-2, 10 and Transplantation Tolerance to Rat Cardiac Allografts Induced by Intrathymic Inoculation

Selective Blockade of Il-15 by Soluble Il-15 Receptor Alpha-Chain Enhances Cardiac Allograft Survival

Donor Derived Exosomes Expressing Lung Associated Self-antigens (collagen V and K Alpha 1 Tubulin) in Acute and Chronic Rejection Following Human Lung Transplantation

Cardiac Allograft Acceptance Induced by Blockade of CD40-CD40L Costimulation is Dependent on CD4+CD25+ Regulatory T Cells

IL-15 is Decreased Upon CsA and FK506 Treatment of Acute Rejection Following Heart Transplantation in Mice.

Synergistic Effect of Low Dose Cyclosporine A and Human Interleukin 10 Overexpression on Acute Rejection in Rat Lung Allotransplantation.